Significantly, when the tumor model with PGK1 knockdown was treated with lapatinib, it exhibited a more pronounced tumor regression compared to the PGK1-knockdown-only group, suggesting that the expression level of PGK1 influences the in vivo tumor response to lapatinib (Figures 7G–I). This evidence concerns the gene PGK1 and neoplasm.